Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 8, 2025, Robert Lisicki, Chief Executive Officer (principal executive officer) and member of the Board of Directors of Zura Bio Limited (the "Company") informed the Company that he is taking a medical leave of absence, effective October 10, 2025. Accordingly, effective October 10, 2025, the Company's Board of Directors appointed Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate Secretary, to serve as the Company's interim Chief Executive Officer and interim principal executive officer, in addition to her current duties.

Biographical and other information for Ms. Davis is set forth in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2025 and is incorporated herein by reference. Ms. Davis is not party to any arrangement or understanding pursuant to which she was appointed as an officer, nor is she party to any transactions required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no family relationships between Ms. Davis and any of the Company's directors or executive officers.